Fresenius SE & Co. (OTCMKTS:FSNUY) Short Interest Up 14,572.5% in April

Fresenius SE & Co. (OTCMKTS:FSNUY) saw a significant increase in short interest in April. As of April 30th, there was short interest totaling 144,231 shares, an increase of 14,572.5% from the April 15th total of 983 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily volume of 357,947 shares, the days-to-cover ratio is currently 0.4 days.

Analyst Ratings Changes

FSNUY has been the topic of a number of recent analyst reports. Morgan Stanley reissued an “overweight” rating on shares of Fresenius SE & Co. in a research note on Monday, April 20th. Citigroup reissued a “buy” rating on shares of Fresenius SE & Co. in a research note on Tuesday, February 3rd. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy”.

Fresenius SE & Co. Trading Down 2.7%

OTCMKTS FSNUY traded down $0.33 on Monday, reaching $11.79. The company had a trading volume of 253,104 shares, compared to its average volume of 96,687. The stock’s 50 day moving average is $13.07 and its 200-day moving average is $14.14. The stock has a market cap of $26.56 billion, a price-to-earnings ratio of 15.72 and a beta of 0.68. The company has a quick ratio of 1.00, a current ratio of 1.32 and a debt-to-equity ratio of 0.47. Fresenius SE & Co. has a 52 week low of $11.28 and a 52 week high of $33.93.

Fresenius SE & Co. (OTCMKTS:FSNUY) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.24 EPS for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The company had revenue of $6.75 billion during the quarter, compared to the consensus estimate of $6.79 billion. Fresenius SE & Co. had a net margin of 6.55% and a return on equity of 10.29%. Equities analysts predict that Fresenius SE & Co. will post 1.05 earnings per share for the current year.

Fresenius SE & Co. Company Profile

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.